18 Sep 2020
Mobocertinib (TAK-788, AP32788; Selective EGFR and HER2 exon 20 insertion mutation tyrosine kinase inhibitor) – Takeda
Parameter | Result |
Objective response rate (ORR) | 43% |
Median duration of response (mDOR) | 13.9 months |
Disease control rate (DCR) | 86% |
Median progression free survival (mPFS) | 7.2 months |
Progressive disease (PD) | 2 pts |
CI Scientists Remarks:
Pivotal trial | Condition | Data readout | Estimated NDA filing in US | Estimated approval |
EXCLAIM | 2L+; locally advanced mNSCLC with EGFR exon 20 mutation | FY’20 | H2 FY’20 | FY’21 |
EXCLAIM-2 | 1L; locally advanced, recurrent or mNSCLC with EGFR exon 20 mutation | FY’22 | NA | FY’23 |
– Dr. Rakshith, CI Scientists
info@ciscientists.com
For a subscription, please provide your email id